EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Chibuzo Sampson, Qiuping Wang, Wuxiyar Otkur, Haifeng Zhao, Yun Lu, Xiaolong Liu iD, Hai-Long Piao iD

Clinical and Translational Medicine · 2023-03 · 13 (3)

DOI: 10.1002/ctm2.1204 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 07.03.2023. Verfasst von Chibuzo Sampson und 6 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Neoplasms. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 352 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China Grants, Dalian Science and Technology Innovation Funding, Liaoning Revitalization Talents Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ubiquitination is one of the most important post‐translational modifications which plays a significant role in conserving the homeostasis of cellular proteins. In the ubiquitination process, ubiquitin is conjugated to target protein substrates for degradation, translocation or activation, dysregulation of which is linked to several diseases including various types of cancers. E3 ubiquitin ligases are regarded as the most influential ubiquitin enzyme owing to their ability to select, bind and recruit target substrates for ubiquitination. In particular, E3 ligases are pivotal in the cancer hallmarks pathways where they serve as tumour promoters or suppressors. The specificity of E3 ligases coupled with their implication in cancer hallmarks engendered the development of compounds that specifically target E3 ligases for cancer therapy. In this review, we highlight the role of E3 ligases in cancer hallmarks such as sustained proliferation via cell cycle progression, immune evasion and tumour promoting inflammation, and in the evasion of apoptosis. In addition, we summarise the application and the role of small compounds that target E3 ligases for cancer treatment along with the significance of targeting E3 ligases as potential cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesNeoplasmsHumansUbiquitinationUbiquitinApoptosis

Stichwörter der Autor:innen

E3 ubiquitin ligasescancertargeted therapyubiquitination

Substanzen

Ubiquitin-Protein LigasesUbiquitin

Autor:innen und Institutionen

  • CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Department of Orthopedics, Dalian Second People's Hospital, Dalian, China.
  • Department of Stomatology, Dalian Medical University, Dalian, China.

ORCID-Profile: Xiaolong Liu, Hai-Long Piao

Förderung

  • National Natural Science Foundation of China Grants
  • Dalian Science and Technology Innovation Funding
  • Liaoning Revitalization Talents Program

Zitieren

APA

Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. L. (2023). The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1204

Vancouver

Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1204

BibTeX
@article{Sampson2023,
  author = {Sampson, Chibuzo and Wang, Qiuping and Otkur, Wuxiyar and Zhao, Haifeng and Lu, Yun and Liu, Xiaolong and Piao, Hai-Long},
  title = {The roles of E3 ubiquitin ligases in cancer progression and targeted therapy},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  doi = {10.1002/ctm2.1204}
}
Kostenlos starten →